Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves ’ orbitopathy

ConclusionsAn individualized safe and effective dose of intravenous methylprednisolone should be established for each patient with GO based on the vascular risk factors, comorbidities, and concomitant drugs. According to the European Group on Graves ’ Orbitopathy (EUGOGO) guidelines, cumulative doses of intravenous methylprednisolone should not exceed 8 g.
Source: Thyroid Research - Category: Endocrinology Source Type: research